Xintong Oral Liquid (Intensive Phase)

ApprovedProtein / enzyme

GGuangzhou University of Traditional Chinese Medicine

Xintong Oral Liquid (Intensive Phase) is one of 44 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Cardiovascular DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Byetta

Foundayo

Lesinurad

EEsperion Therapeutics, Inc.

Phase 3

1 4

Rimonabant

Sanofi

Phase 3

1 5

Triclosan

CColgate Palmolive

Phase 3

1 6

Xintong Oral Liquid (Intensive Phase)

GGuangzhou University of Traditional Chinese Medicine

Approved

1 7

Repatha

Amgen

Preclinical

5 8

Praluent

Regeneron

Preclinical

1 9

Calciferol

Alnylam Pharmaceuticals

Preclinical

1 10

Benicar

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Post-ApprovalNot yet recruiting

Cardiovascular Disease

NCT07088523

Clinical

Trials by Indication[1]

Cardiovascular Disease1 trial

Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study

Not yet recruiting·GGuangzhou University of Traditional Chinese Medicine·Phase 4·NCT07088523·4,205 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Xintong Oral Liquid (Intensive Phase). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Xintong Oral Liquid (Intensive Phase) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Xintong Oral Liquid (Intensive Phase). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Approved[1]
Company: GGuangzhou University of Traditional Chinese Medicine

Xintong Oral Liquid (Intensive Phase)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Cardiovascular Disease1 trial

References

Drug Info

Quick Facts

Related News